Exploration of scaffolds from natural products with antiplasmodial activities, currently registered antimalarial drugs and public malarial screen data

In light of current resistance to antimalarial drugs, there is a need to discover new classes of antimalarial agents with unique mechanisms of action. Identification of unique scaffolds from natural products with in vitro antiplasmodial activities may be the starting point for such new classes of antimalarial agents. We therefore conducted scaffold diversity and comparison analysis of natural products with in vitro antiplasmodial activities (NAA), currently registered antimalarial drugs (CRAD) and malaria screen data from Medicine for Malaria Ventures (MMV). The scaffold diversity analyses on the three datasets were performed using scaffold counts and cumulative scaffold frequency plots. Scaffolds from the NAA were compared to those from CRAD and MMV. A Scaffold Tree was also generated for each of the datasets and the scaffold diversity of NAA was found to be higher than that of MMV. Among the NAA compounds, we identified unique scaffolds that were not contained in any of the other compound datasets. These scaffolds from NAA also possess desirable drug-like properties making them ideal starting points for antimalarial drug design considerations. The Scaffold Tree showed the preponderance of ring systems in NAA and identified virtual scaffolds, which may be potential bioactive compounds

Consistency of Reported Barriers for Colorectal Cancer Screening Among Adults Who Have Never Been Screened

Morbidity and mortality from colorectal cancer can be decreased by addressing patient barriers to colorectal cancer screening; especially among adults who have never been screened. Assessing changes in barriers over time may help practitioners better tailor interventions to address patient barriers. We assessed among adults ages 50 -75 who have never been screened for colorectal cancer (CRC) which barriers predict prospective screening. A sample of 560 adults who had never been screened, recruited from Growth for Knowledge’s online panel, completed a baseline and a six-month follow-up survey. Both surveys assessed screening barriers after an online intervention that involved conveying tailored comparative risk estimates and message framing. Among those who did not get screened, we examined the consistency between reported barriers at baseline and at six-month follow-up. At baseline, participants identified 27 barriers; some reported no barriers. Among those never screened (n = 362), there was a significant increase from baseline to follow-up in five barriers: ‘time/too busy’, ‘no symptoms’, ‘in good health’, ‘no motivation’, and ‘hadn’t thought about it’. Reporting ‘no barriers’ at baseline was a significant predictor of being screened at follow-up (OR = 3.67, 95% CI = 1.44-9.30, p \u3c .007). Among people who have never been screened, interventions should focus on addressing the most consistently reported barriers (i.e., ‘time/too busy’, and on improving knowledge and beliefs about who should be screened and when, as well as attitudes toward screening, to design more efficacious and tailored interventions

Guidance for reconciling patent rights and disclosure of findings at scientific meetings

Open collaboration and sharing of information among scientists at scientific meetings can foster innovation and discovery. However, such sharing can be at odds with potential patenting and commercialization objectives. This tension may be mitigated if certain procedures are followed in the context of scientific meetings. The article first discusses what makes a scientific finding patentable and then sets out four specific patent issues for scientists to consider before attending a scientific meeting and sharing their research. Finally, it provides recommendations on how scientists can best protect their intellectual property rights while sharing information at scientific meetings

Developing patient-friendly genetic and genomic test reports: formats to promote patient engagement and understanding

10.1186/s13073-014-0058-6Genome Medicine675

Risk perception and concern among brothers of men with prostate carcinoma

BACKGROUND It is important for clinicians, researchers, and others who shape public health policy to understand the demographic correlates and psychologic factors that drive health behaviors, such as screening for early detection of cancer, particularly among individuals at high risk for developing the disease. METHODS One-hundred eleven men whose brothers were diagnosed with prostate carcinoma completed a computer-assisted telephone interview aimed to assess their perception of absolute risk and concern about developing prostate carcinoma over the next 10 years and across their lifetime. Comparisons were made between selected demographic, behavioral, family pedigree characteristics, and measures of perceived risk and concern. RESULTS The majority of men perceived their personal risk of developing prostate carcinoma to be ≥ 50%. Men who at the time of the interview were younger than their affected brother were significantly more concerned about prostate carcinoma and perceived their risk to be higher than men who were older than their brother. Estimates of personal risk and concern were also uniformly higher among men with more than one first-degree relative affected with prostate carcinoma compared to men with only one affected first-degree relative. Risk perception and concern about an impending prostate carcinoma diagnosis were associated with the use of supplements marketed for prostate health. CONCLUSIONS The findings indicated that birth order in relation to a brother diagnosed with prostate carcinoma is significantly associated with risk perception and concern in unaffected family members. These results highlight the need for further study of the familial dynamics and characteristics that drive health behaviors and stress importance of public health education to inform men of personal risk assessment as well as the risks and benefits of screening. These studies ultimately can contribute to the success of strategies for the primary prevention and early detection of cancer. Cancer 2004;100:1537–44. © 2004 American Cancer Society.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34386/1/20121_ftp.pd

How People with Low and High Graph Literacy Process Health Graphs: Evidence from Eye-tracking

Graphs facilitate the communication of important quantitative information, often serving as effective decision support tools. Yet, graphs are not equally useful for all individuals, as people differ substantially in their graph literacy-the ability to understand graphically presented information. Although some features of graphs can be interpreted using spatial-to-conceptual mappings that can be established by adults and children with no graphing experience (e.g., "higher bars equal larger quantities"), other features are linked to arbitrary graph conventions (e.g., axes labels and scales). In two experiments, we examined differences in the processes underlying the comprehension of graphs presenting medical information in individuals with low and high graph literacy. Participants' eye movements were recorded while they interpreted graphs in which information in conventional features was incongruent with that conveyed by spatial features. Results revealed that participants with low graph literacy more often relied on misleading spatial-to-conceptual mappings and misinterpreted the data depicted. Higher graph literacy was often associated with more time spent viewing the conventional features containing essential information for accurate interpretations. This suggests that individuals with high graph literacy are better able to identify the task-relevant information in graphs, and thus attend to the relevant features to a larger extent. Theoretical, methodological, and prescriptive implications for customization of decision-support systems are discussed

On the Normalization and Visualization of Author Co-Citation Data Salton's Cosine versus the Jaccard Index

The debate about which similarity measure one should use for the normalization in the case of Author Co-citation Analysis (ACA) is further complicated when one distinguishes between the symmetrical co-citation--or, more generally, co-occurrence--matrix and the underlying asymmetrical citation--occurrence--matrix. In the Web environment, the approach of retrieving original citation data is often not feasible. In that case, one should use the Jaccard index, but preferentially after adding the number of total citations (occurrences) on the main diagonal. Unlike Salton's cosine and the Pearson correlation, the Jaccard index abstracts from the shape of the distributions and focuses only on the intersection and the sum of the two sets. Since the correlations in the co-occurrence matrix may partially be spurious, this property of the Jaccard index can be considered as an advantage in this case

Modular Synthesis of Diverse Natural Product-like Macrocycles: Discovery of Hits with Antimycobacterial Activity

A modular synthetic approach was developed in which variation of the triplets of building blocks used enabled systematic variation of the macrocyclic scaffolds prepared. The approach was demonstrated in the synthesis of 17 diverse natural product-like macrocyclic scaffolds of varied (12-20-membered) ring size. The biological relevance of the chemical space explored was demonstrated through the discovery of a series of macrocycles with significant antimycobacterial activity

Mapping Patent Classifications: Portfolio and Statistical Analysis, and the Comparison of Strengths and Weaknesses

The Cooperative Patent Classifications (CPC) jointly developed by the European and US Patent Offices provide a new basis for mapping and portfolio analysis. This update provides an occasion for rethinking the parameter choices. The new maps are significantly different from previous ones, although this may not always be obvious on visual inspection. Since these maps are statistical constructs based on index terms, their quality--as different from utility--can only be controlled discursively. We provide nested maps online and a routine for portfolio overlays and further statistical analysis. We add a new tool for "difference maps" which is illustrated by comparing the portfolios of patents granted to Novartis and MSD in 2016.Comment: Scientometrics 112(3) (2017) 1573-1591; http://link.springer.com/article/10.1007/s11192-017-2449-